v3.25.1

Critical accounting judgments and key sources of estimation uncertainty - IFRS 15 - Revenue recognition Gilead (Details) |  | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | ---
May 30, 2024 USD ($) | Dec. 31, 2024 EUR (€) | Dec. 31, 2024 USD ($) | Dec. 31, 2024 USD ($) | Dec. 31, 2023 EUR (€) | Dec. 31, 2022 EUR (€)
Critical accounting estimates and judgments |  |  |  |  |  |
Contribution to Alfasigma |  | € (40,000,000) |  |  |  |
Deferred income |  | 1,071,352,000 |  |  | € 1,327,463,000 | € 1,989,230,000
Goodwill |  | 70,010,000 |  |  | 69,557,000 | 69,813,000
Intangible assets other than goodwill |  | € 164,862,000 |  |  | 127,906,000 |
Duration Of Forecast Of Future Cash Flows |  | 16 years | 16 years |  |  |
Minimum Duration Of Forecast Of Future Cash Flows For Which It Becomes Less verifiable And More Assumptions. |  | 5 years | 5 years |  |  |
Filgotinib Performance Obligation Member |  |  |  |  |  |
Critical accounting estimates and judgments |  |  |  |  |  |
Deferred income |  |  |  |  | 26,300,000 |
Exclusive rights |  |  |  |  |  |
Critical accounting estimates and judgments |  |  |  |  |  |
Intangible assets other than goodwill |  | € 114,456,000 |  |  | 71,929,000 |
Cell Point Acquisition |  |  |  |  |  |
Critical accounting estimates and judgments |  |  |  |  |  |
Goodwill |  | 62,400,000 |  |  |  | 62,444,000
Contingent consideration [member] | Cell Point Acquisition |  |  |  |  |  |
Critical accounting estimates and judgments |  |  |  |  |  |
Contingent Consideration |  | € 20,600,000 |  |  | 21,000,000 |
Adaptimmune Collaboration [member] |  |  |  |  |  |
Critical accounting estimates and judgments |  |  |  |  |  |
Upfront Exclusivity Payment | $ | $ 70,000,000 |  |  |  |  |
Research and development funding payment. | $ | $ 15,000,000 |  |  |  |  |
Upfront Exclusive Research And Development Payable | $ |  |  |  | $ 15,000,000 |  |
Deferred Expenses | $ |  |  |  | 15,000,000 |  |
Adaptimmune Collaboration [member] | Exclusive rights |  |  |  |  |  |
Critical accounting estimates and judgments |  |  |  |  |  |
Intangible assets other than goodwill | $ |  |  |  | $ 70,000,000 |  |
Gilead | Collaboration agreement for filgotinib |  |  |  |  |  |
Critical accounting estimates and judgments |  |  |  |  |  |
Deferred income |  |  |  |  | € 26,268,000 | € 456,352,000
First Payment [member] | Adaptimmune Collaboration [member] |  |  |  |  |  |
Critical accounting estimates and judgments |  |  |  |  |  |
Upfront Exclusivity Payment | $ |  |  | $ 70,000,000 |  |  |
Second Payment [member] | Adaptimmune Collaboration [member] |  |  |  |  |  |
Critical accounting estimates and judgments |  |  |  |  |  |
Research and development funding payment. | $ |  |  | $ 15,000,000 |  |  |

X
- Definition The amount of contingent consideration. + References No definition available. + Details
Name: | glpg_ContingentConsideration
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of Contribution For R&D Costs Payable To Alfasigma + References No definition available. + Details
Name: | glpg_ContributionForRDCostsPayableToAlfasigma
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of R&D deferred expenses + References No definition available. + Details
Name: | glpg_DeferredExpenses
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The duration of forecast of future cash flows used in the calculation of recoverable amount of cash-generating units. + References No definition available. + Details
Name: | glpg_DurationOfForecastOfFutureCashFlows
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The minimum duration of forecast of future cash flows used in the calculation of recoverable amount of cash-generating units for which it becomes less verifiable and more assumptions. + References No definition available. + Details
Name: | glpg_MinimumDurationOfForecastOfFutureCashFlowsForWhichItBecomesLessVerifiableAndMoreAssumptions.
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of research and development payment made. + References No definition available. + Details
Name: | glpg_ResearchAndDevelopmentPayment
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of upfront exclusivity payment payable subject to the start of dosing in the proof-of-concept trial. + References No definition available. + Details
Name: | glpg_UpfrontExclusiveResearchAndDevelopmentPayable
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of upfront exclusivity payment made. + References No definition available. + Details
Name: | glpg_UpfrontExclusivityPayment
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, other than contract liabilities. [Refer: Contract liabilities] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 55 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 78 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DeferredIncomeOtherThanContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfOffsettingOfFinancialAssetsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Total for all business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 36 -IssueDate 2024-01-01 -Paragraph 134 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_a&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 36 -IssueDate 2024-01-01 -Paragraph 135 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_135_a&doctype=Standard -URIDate 2024-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2024-01-01 -Paragraph B67 -Subparagraph d -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B -URIDate 2024-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 54 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_c&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_Goodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2024-01-01 -Paragraph 118 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 54 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_c&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_IntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | ifrs-full_PerformanceObligationsAxis=glpg_FilgotinibPerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=glpg_CellPointAcquisitionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_ContingentConsiderationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_AdaptimmuneCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_GileadSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForFilgotinibMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsScenarioAxis=glpg_FirstPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsScenarioAxis=glpg_SecondPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |